MEIP News Alert Mei Pharma Inc (MEIP) 3.90 12/25/2014 15:16:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mei Pharma Inc (MEIP) 3.90 $MEIP

NIRI San Diego Elects 2015 Board Members
PR Newswire - Mon Dec 22, 3:05PM CST
The San Diego Chapter of the National Investor Relations Institute (NIRI San Diego) has announced the election of its board of directors for 2015. The incoming board includes a newly formed, novel Co-president position to appropriately balance the leadership skills of three returning board members. The chapter has also formed an advisory committee comprised of out-going board members Gwen Rosenberg, Jane Booth, Karen Fisher, and John Stoepler, to recognize their long-term contributions to NIRI San Diego.
RGLS: 14.78 (+0.24), ENTR: 2.26 (-0.06), MEIP: 3.90 (+0.11)

MEI Pharma Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome
PR Newswire - Mon Dec 22, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the clinical response milestone has been reached in the Company's ongoing Phase II study of its investigational drug candidate Pracinostat in combination with a hypomethylating agent (HMA) in patients with myelodysplastic syndrome (MDS) who previously failed treatment with single-agent HMA.
MEIP: 3.90 (+0.11)

MEI Pharma concludes public offering of 11.5m common shares, including exercise in underwriters' option
M2 - Thu Dec 18, 7:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) said on Wednesday that it has closed the public offering of 11,500,000 shares of its common stock.
MEIP: 3.90 (+0.11)

Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), INCY: 71.57 (+1.99), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)

MEI Pharma Completes Public Offering of Common Stock
PR Newswire - Wed Dec 17, 3:05PM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares of common stock that were issued upon exercise, in full, of the option to purchase additional shares granted to the underwriters. Exercise of the full option to purchase additional shares by the underwriters increased the gross proceeds to the Company, before underwriting discounts and expenses, from approximately $40.0 million to approximately $46.0 million.
MEIP: 3.90 (+0.11)

MEI Pharma prices public offering of common shares at USD4.00 per share
M2 - Mon Dec 15, 6:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) said on Friday that it has priced public offering of 10,000,000 shares of its common stock.
MEIP: 3.90 (+0.11)

Nasdaq stocks posting largest volume increases
AP - Fri Dec 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ISIG: 3.78 (+0.02), HCCI: 11.76 (-0.41), ANCB: 20.35 (-0.10), MEIP: 3.90 (+0.11)

MEI Pharma Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Fri Dec 12, 7:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of $4.00 per share, for total gross proceeds (before underwriting discount and commissions and estimated expenses) of approximately $40 million. The Company has granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of its common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.
MEIP: 3.90 (+0.11)

Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 21.47 (-0.55), CLDN: 18.54 (+0.85), BRID: 7.01 (-0.45), HCCI: 11.76 (-0.41), MIND: 5.77 (+0.14), ROSE: 23.18 (-0.45), OBAS: 7.04 (-0.46), MEIP: 3.90 (+0.11), IESC: 7.79 (+0.07), SRPT: 13.88 (+0.47), CONN: 18.23 (+1.23), LINE: 10.93 (-0.32), DGLY: 15.62 (+0.82)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST

SD: 2.02 (-0.04), FRO: 2.43 (-0.01), ABCO: 49.30 (-0.58), ZAZA: 3.20 (+0.70), JMEI: 15.09 (+0.21), SGMO: 14.20 (+0.14), TGTX: 16.03 (+0.33), MEI: 36.68 (+0.62), WLT: 1.45 (-0.02), NSPR: 0.70 (-0.02), VII: 1.83 (+0.38), CVTI: 26.18 (+0.05), MEIP: 3.90 (+0.11), ALDR: 25.67 (+0.43), CALA: 22.33 (+1.16), CGG: 6.19 (-0.05), SPP: 1.63 (+0.18), DSCO: 1.17 (+0.01), KPTI: 37.78 (+1.28), HBOS: 25.74 (+0.06)

MEI Pharma anticipates USD45m from public offering of common shares
M2 - Thu Dec 11, 6:22AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) announced on Wednesday that it intends to offer up to USD45m shares of its common stock in a public offering.
MEIP: 3.90 (+0.11)

MEI Pharma Announces $45 Million Proposed Public Offering of Common Stock
PR Newswire - Wed Dec 10, 3:01PM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer up to $45,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
MEIP: 3.90 (+0.11)

MEI Pharma Reports Significant Clinical Activity In Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia
PR Newswire - Mon Dec 08, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, reported significant clinical activity from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). Interim data from 33 evaluable patients treated at 15 centers were presented at the American Society of Hematology (ASH) Annual Meeting in San Francisco on Saturday.
MEIP: 3.90 (+0.11)

MEI Pharma appoints Dr Kevan Clemens to board
M2 - Fri Dec 05, 4:31AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) disclosed on Thursday that Dr Kevan E. Clemens, PhD has joined its board of directors.
MEIP: 3.90 (+0.11)

MEI Pharma Announces Election of Pharmaceutical Industry Veteran Kevan Clemens to Board of Directors
PR Newswire - Thu Dec 04, 5:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the election of Kevan E. Clemens, Ph.D., to its Board of Directors at the Company's Annual Meeting of Stockholders yesterday. Dr. Clemens has a long and distinguished career in the pharmaceutical industry, highlighted by his role as head of Global Oncology at Hoffmann-La Roche. His election increases the size of MEI Pharma's board to eight members, including seven independent directors.
MEIP: 3.90 (+0.11)

MEI Pharma Completes Enrollment in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia
PR Newswire - Tue Dec 02, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia. The open-label study enrolled a total of 50 patients at 15 clinical sites in the U.S.
MEIP: 3.90 (+0.11)

MEI Pharma To Host Analyst And Investor Event
PR Newswire - Mon Dec 01, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its 2nd Annual Analyst and Investor Event on Monday, December 8, 2014 at 6:00 p.m. Pacific time at the Westin St. Francis in San Francisco. The event will feature a clinical update by Robert D. Mass, MD, Chief Medical Officer of MEI Pharma, along with a presentation by Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center. A live webcast of the event can be accessed at www.meipharma.com. A replay will be available approximately one hour after its conclusion.
MEIP: 3.90 (+0.11)

MEI Pharma To Host Annual Meeting Of Stockholders
PR Newswire - Wed Nov 26, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific time on Wednesday, December 3, 2014, at the offices of Morgan, Lewis & Bockius LLP, located at One Market, Spear Street Tower, San Francisco, CA 94105. Stockholders of record at the close of business on October 3, 2014 are entitled to receive notice of and vote at the Annual Meeting. A live webcast of the meeting will be accessible at www.meipharma.com. A replay will be available approximately one hour after its conclusion.
MEIP: 3.90 (+0.11)

MEI Pharma to Present at Stifel Healthcare Conference
PR Newswire - Wed Nov 12, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference on Wednesday, November 19, 2014 at 8:00 a.m. Eastern time from the New York Palace Hotel. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 3.90 (+0.11)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 100

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 155

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 128

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 140

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 125

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 201

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 198

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 84

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 10

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading

Top 5 Most Recently Viewed Articles

Mori Building Boosts Investment in SL Green’s Premier Tower

Updated Category News Views 252

Mori Building Increases Stake in Iconic One Vanderbilt Avenue In a significant development within New York’s skyline, Mori Building Co., Ltd. has expanded its investment in One Vanderbilt Avenue, acquiring an additional 5.0% interest. This comes on the heels of their earlier investment of 11.0% in 2024, marking a strong commitment to this architectural marvel situated...

Continue Reading
Vegamour Welcomes Michelle Miller as Chief Marketing Officer

Updated Category News Views 415

Vegamour Welcomes New Chief Marketing Officer Michelle Miller Vegamour is excited to announce the appointment of Michelle Miller as its first Chief Marketing Officer. A well-regarded figure in the beauty industry, Michelle brings years of experience and a proven track record of success to the company. Experience and Achievements of Michelle Miller Before joining Vegamour,...

Continue Reading
Streamlined Financing Solutions Transform Insurance Payments

Updated Category News Views 107

Revolutionizing Insurance Payments with Innovative Solutions FIRST Insurance Funding, a division of Lake Forest Bank & Trust Company, N.A., has been at the forefront of premium financing for many years. Their recent integration with ePayPolicy is set to elevate the insurance payment process, making it more accessible and user-friendly for providers and insureds alike....

Continue Reading
Range Resources Delivers Strong Q1 Results with Growth Plans

Updated Category News Views 238

Impact of Q1 2025 Results on Range Resources Range Resources Corporation (NYSE: RRC) recently revealed its first quarter financial performance, showcasing robust operating results. The company reported cash flow from operating activities reaching $330 million, highlighting strong operational efficiency. Financial Highlights for the First Quarter Key Financial Metrics In...

Continue Reading
Investing in Tomorrow: The Untapped Potential of DexCom and Roku

Updated Category News Views 122

Investing in stocks can feel like a rollercoaster ride, especially when markets take a nosedive. Historical trends remind us that, over time, stocks often bounce back. Smart investors seize opportunities during downturns to snag quality shares at bargain prices. This principle of 'buy low' remains as relevant as ever. DexCom's Dip: Opportunity or Red Flag? DexCom’s...

Continue Reading